Chongqing Kangle Pharmaceutical

Chongqing Kangle Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, and large-scale manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. A subsidiary of Chongqing Pharscin Pharmaceutical, the company is globally recognized as a major supplier of anti-malarial drugs, including artemisinin derivatives like artemether and lumefantrine. Their product portfolio also extends to cardiovascular treatments, specifically statins such as atorvastatin and rosuvastatin. Kangle Pharmaceutical operates high-standard GMP manufacturing facilities and maintains a strong presence in both domestic and international markets, including collaborations with global health organizations. The company is a designated production base for anti-malarial drugs by the World Health Organization (WHO) and the Chinese government. It plays a critical role in the global supply chain for essential medicines used to treat malaria and chronic metabolic conditions.